

ANTIBODY/TARGETED-DRUG CONJUGATES

6-8 November 2019, Queen's University Belfast, Belfast, Northern Ireland, UK

The Targeted Drug-Conjugates Delivery Conference – New Developments & Updates FIRST CIRCULAR AND CALL FOR PARTICIPATION FOR ATDC 2019

The concept of using biologics and particles including monoclonal antibodies to deliver drugs to disease targets such as cancer cells has been explored for decades, with early work surrounding non-specific targets and drugs with low potencies. These studies highlighted the importance of critical parameters, such as antigen and tumor target selection, linker stability, drug potency, pharmacokinetics and conjugation methodology, in developing effective targeted drug conjugates with acceptable safety/toxicity profiles.

The third ATDC New Developments & Updates conference to be held in Belfast, Northern Ireland, UK in November 2019 will aim to examine the concept and future of targeted drug delivery systems to include antibodies/bispecific antibodies/proteins/nanoparticles and other biologics.

The ATDC 2019 scientific programme will include keynote lectures, contributed papers and poster presentations emphasising all key aspects and recent developments surrounding targeted drug delivery systems.

Abstracts for oral and poster presentation are called for – please see the reverse page for abstract submission details.

SCIENTIFIC ADVISORY PANEL

Conference Chairman: Chris Scott (*Queen's University Belfast, Belfast, UK*)

John A. Flygare (*Merck Inc., USA*)

Greg Bleck (*Catalent Pharma Solutions, Somerset, New Jersey, USA*)

Victor Goldmacher (*Forbius Inc., Austin, Texas, USA*)

Roger R. Beerli (*NBE-Therapeutics LLC, Basel, Switzerland*)

Michael Firer (*Ariel University, Ariel, Israel*)

Alain Beck (*Centre d'Immunologie Pierre Fabre, St Julien-en-Genevois, France*)

Philip Howard (*MedImmune/Spirogen Ltd, London, UK*)

Peter Hofland (*InPress Media Group, Phoenix, Arizona, USA*)

David Rabuka (*Catalent Pharma Solutions, Somerset, New Jersey, USA*)

Peter Park (*Bicycle Therapeutics Inc., Cambridge, Massachusetts, USA*)

Hendrik Jan Houthoff (*LinXis Pharmaceuticals BV, Amsterdam, The Netherlands*)

Deyarina Gonzalez (*Swansea University Medical School, Swansea, Wales, UK*)

Steve Conlan (*Swansea University Medical School, Swansea, Wales, UK*)

Ulrich Storz (*Michalski Hattermann & Partners, Dusseldorf, Germany*)

Aad van de Leur (*Synthon Biopharmaceuticals BV, Nijmegen, The Netherlands*)

Floris van Delft (*Synaffix BV, Oss, The Netherlands*)

Graham Cotton (*Almac Discovery, Belfast, Northern Ireland, UK*)

Estelle McLean (*Almac Discovery, Belfast, Northern Ireland, UK*)

Vijay Chudasama (*University College London, London, UK*)

CONFERENCE SCOPE AND TOPICS

Novel ADC targets/ADC target discovery/target disease indications (including non-cancer targets) · Novel payloads/modes of action (beyond tubulin binders) · Biological components (antibody & antibody-like formats; molecularly defined conjugation sites) · Chemical components: Linker/payload combinations; optimization of linker chemistry; cleavable linkers · Next generation ADCs (site-specifically conjugated, including enzymatic conjugation Immunotoxins · Chemistry approaches: mediating high toxicity of new warheads currently in use · Chemical modifications of ADC structure and linkers Improving the therapeutic index – toxicity reduction efforts avoiding efficacy reduction · Other carrier/delivery possibilities beyond antibodies and bispecific antibodies (nanoparticles, peptides, aptamers, hormones and their analogues, small molecules, liposomes, vitamins) · Manufacturing/Regulatory issues · Process development (robustness, scalability) · Clinical stage ADCs/ongoing clinical trials, clinical translation

Abstract Submissions

The ATDC 2019 Scientific Advisory Panel require authors to submit a one page abstract for each paper they wish to be considered for inclusion in the oral and/or poster programs during ATDC 2019. The one page abstract should contain sufficient information for the Scientific Advisory Panel to be able to make a valid decision as to the intrinsic merit of the paper and its relevance to the aims of the conference. Authors should indicate on the reply form whether they prefer oral or poster presentation. Proposals are also invited for panel discussions and special workshops – these special sessions may be scheduled during the daytime conference timetable or alternatively can be allocated as either breakfast or evening sessions.

Abstract proposals should be sent for the attention of John Herriot at Meetings Management (ATDC 2019 Conference Organisers). Authors should send their abstract(s) by e-mail to: jherriot@meetingsmgmt.u-net.com (please attach abstracts as Word documents).

Closing date for submissions intended for oral presentation: **Friday 3rd May 2019**. Authors will be informed of the status of their contribution(s) in June 2019. Closing date for submissions intended for poster presentation: **Friday 18th October 2019**.

Publication

Abstracts of all papers to be presented (oral and poster) will be included on a USB device which will be distributed to delegates on registration. All submissions will be refereed in the normal fashion and will be published subsequent to the conference.

Participation

All non-invited speakers will be expected to register as delegates to ATDC 2019. Registration will require speakers to pay a registration fee to attend the conference. Travel and accommodation expenses are the responsibility of each non-invited speaker and no direct compensation is awarded for speakers at ATDC 2019. **Your submission of an abstract testifies to the fact that you will accept these financial conditions.**

CALL FOR PARTICIPATION REPLY FORM

- I wish to be placed on the mailing list to receive further information on ATDC 2019
- I am interested in presenting a paper/poster (abstract attached) – please indicate preferred presentation method

Title of abstract:

Intended session:

Title (Prof, Dr, Mr, Mrs, Ms): First Name:

Last Name: Organisation:

Address:

Postal/Zip Code: Country:

Telephone: Fax:

E-mail (Please Type/Print):

- My organisation is interested in sponsoring ATDC 2019 Please send me details of exhibition/delegate wallet service

REQUEST DETAILS OF FUTURE EVENTS

- VIRUS-LIKE PARTICLE & NANO-PARTICLE VACCINES** – June 2020, Riga, Latvia
- CANCER VACCINES 2020 VISION** – July 2020, Venue to be confirmed

PLEASE RETURN THIS FORM TO:

JOHN HERRIOT, ATDC 2019, MEETINGS MANAGEMENT

Danehurst, Nore Lane, Hascombe, Godalming, Surrey GU8 4JT, United Kingdom

Telephone: +44 (0)1483 427770 E-mail: jherriot@meetingsmgmt.u-net.com Website: www.meetingsmanagement.com/atdc_2019